264 related articles for article (PubMed ID: 26483088)
21. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
Yang YS; Zhang X; Xiong Z; Chen X
Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
[TBL] [Abstract][Full Text] [Related]
23. Combined whole-body dynamic and static PET/CT with low-dose [
Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
[TBL] [Abstract][Full Text] [Related]
24. Novel series of (177)Lu-labeled bombesin derivatives with amino acidic spacers for selective targeting of human PC-3 prostate tumor cells.
Pujatti PB; Santos JS; Couto RM; Melero LT; Suzuki MF; Soares CR; Grallert SR; Mengatti J; De Araújo EB
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):310-23. PubMed ID: 21532543
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
DeGrado TR; Baldwin SW; Wang S; Orr MD; Liao RP; Friedman HS; Reiman R; Price DT; Coleman RE
J Nucl Med; 2001 Dec; 42(12):1805-14. PubMed ID: 11752077
[TBL] [Abstract][Full Text] [Related]
26. Dynamic 11C-Choline PET / CT for the primary diagnosis of prostate cancer.
Golan S; Nidam M; Bernstine H; Baniel J; Groshar D
Int Braz J Urol; 2018; 44(5):900-905. PubMed ID: 30088719
[TBL] [Abstract][Full Text] [Related]
27. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
28. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
[TBL] [Abstract][Full Text] [Related]
30. A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.
Yan Y; Chen K; Yang M; Sun X; Liu S; Chen X
Amino Acids; 2011 Jul; 41(2):439-47. PubMed ID: 20936525
[TBL] [Abstract][Full Text] [Related]
31. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
[TBL] [Abstract][Full Text] [Related]
32. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
Schroeder RP; Müller C; Reneman S; Melis ML; Breeman WA; de Blois E; Bangma CH; Krenning EP; van Weerden WM; de Jong M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1386-96. PubMed ID: 20182713
[TBL] [Abstract][Full Text] [Related]
33. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.
Piert M; Park H; Khan A; Siddiqui J; Hussain H; Chenevert T; Wood D; Johnson T; Shah RB; Meyer C
J Nucl Med; 2009 Oct; 50(10):1585-93. PubMed ID: 19759109
[TBL] [Abstract][Full Text] [Related]
34. [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice.
Zheng QH; Stone KL; Mock BH; Miller KD; Fei X; Liu X; Wang JQ; Glick-Wilson BE; Sledge GW; Hutchins GD
Nucl Med Biol; 2002 Nov; 29(8):803-7. PubMed ID: 12453589
[TBL] [Abstract][Full Text] [Related]
35. A Pilot Study of Dynamic
Lu M; Lindenberg L; Mena E; Turkbey B; Seidel J; Ton A; McKinney Y; Eclarinal P; Merino M; Pinto P; Choyke P; Adler S
Mol Imaging Biol; 2022 Jun; 24(3):444-452. PubMed ID: 34724140
[TBL] [Abstract][Full Text] [Related]
36. Choline PET for monitoring early tumor response to photodynamic therapy.
Fei B; Wang H; Wu C; Chiu SM
J Nucl Med; 2010 Jan; 51(1):130-8. PubMed ID: 20008981
[TBL] [Abstract][Full Text] [Related]
37. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.
Pillarsetty N; Punzalan B; Larson SM
J Nucl Med; 2009 Oct; 50(10):1709-14. PubMed ID: 19759108
[TBL] [Abstract][Full Text] [Related]
38.
Grkovski M; Gharzeddine K; Sawan P; Schöder H; Michaud L; Weber WA; Humm JL
J Nucl Med; 2018 Nov; 59(11):1672-1678. PubMed ID: 29626123
[TBL] [Abstract][Full Text] [Related]
39. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer.
Schillaci O; Calabria F; Tavolozza M; Cicciò C; Carlani M; Caracciolo CR; Danieli R; Orlacchio A; Simonetti G
Nucl Med Commun; 2010 Jan; 31(1):39-45. PubMed ID: 19972635
[TBL] [Abstract][Full Text] [Related]
40. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML
J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
